The latest Investing Matters Podcast with Jean Roche, Co-Manager of Schroder UK Mid Cap Investment Trust has just been released. Listen here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksBenchmark Holdings Regulatory News (BMK)

Share Price Information for Benchmark Holdings (BMK)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 43.10
Bid: 43.10
Ask: 46.90
Change: 1.30 (2.97%)
Spread: 3.80 (8.817%)
Open: 43.10
High: 43.10
Low: 43.10
Prev. Close: 43.70
BMK Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Trading Update and Notice of Results

26 May 2016 07:00

RNS Number : 3431Z
Benchmark Holdings PLC
26 May 2016
 

26 May 2016

Benchmark Holdings plc("Benchmark", the "Company" or the "Group")

Trading Update and Notice of Results

· Trading in line with management's expectations

· INVE integration progressing well with first operational synergies realised

· Braintree manufacturing facility expected to enter commissioning by September

· Encouraging progress in development pipeline

Benchmark, the biotechnology and food chain sustainability business, announces that Group performance for the six months to 31 March 2016 was in line with management's expectations.

The integration of INVE is progressing well, with operational synergies being realised through utilisation of INVE's distribution network to support the launch of the first of our new aquaculture vaccines from the Animal Health pipeline, and use of INVE's products in the Breeding and Genetics division's lumpfish programme. The Advanced Animal Nutrition division performed slightly ahead of management's expectations.

The Animal Health, Sustainability Science and Technical Publishing divisions all performed in line with management's expectations.

Benchmark's development pipeline is progressing well, with a new aquaculture vaccine targeted at the Mediterranean region expected to be commercialised this year. This vaccine was developed, is manufactured and will be distributed entirely by the Group. New vaccine manufacturing facilities at Braintree and aquaculture trials facilities at Ardtoe are coming online to provide the vital infrastructure to deliver the Group's development portfolio.

In line with guidance provided at year end, the Breeding and Genetics division has had a difficult first half as a result of the closure of the Chilean border to Icelandic salmon eggs. Recovery was slower than anticipated, aggravated by lower stocking in the Chilean industry in response to environmental challenges, with sales significantly impacted. The underperformance in this division was balanced by positive performance elsewhere in the Group.

El Niño has had an impact on the climate in South East Asia and Latin America and the algal bloom in Chile has reduced total salmon biomass across the Chilean industry. Climatic factors can have a significant influence on sales of aquaculture health products, salmon eggs or advanced nutrition, and while management continues to monitor the situation, the Company remains on track for the full year.

The long term drivers of growth in the Company's sectors are clearly positive. The Group's targeted expansion now allows Benchmark to offer an integrated package of products and services to its customers, and key account management is being introduced to strengthen the Group's ability to exploit the significant opportunities in the markets it serves.

Benchmark expects to announce its interim results for the six months to 31 March 2016 on Tuesday, 28 June 2016.

Commenting on trading, Benchmark's Chief Executive Officer, Malcolm Pye, said:

"We have had a busy first half and made significant progress as we continue to develop Benchmark into a group that comprehensively serves the needs of our customers. The quality of our divisional management teams has been evident during the integration of INVE as they continue their work to realise synergies available to the enlarged Group.

"Our strategy of diversification is showing its value and importance, with half year performance in line with our expectations, despite the disruption caused by the border situation in Chile.

"Having completed the process of creating a scalable group structure, the outlook for Benchmark is extremely promising. The markets we serve are not transitory, but are the fundamental building blocks of a sustainable food chain. With all of the pressures being placed upon these industries, we are an increasingly important partner to our customers. Against this backdrop, we will continue our work to achieve our long term potential and create value, by launching the new products our customers urgently need and growing sales."

 

-Ends-

 

For further information, please contact:

 

Benchmark Holdings plc

Tel: 020 7920 3150

Malcolm Pye, CEO

 

Roland Bonney, COO

Rachel Aninakwah, Communications

Cenkos Securities PLC

Tel: 020 7397 8900

Ivonne Cantu / Stephen Keys (NOMAD)

Russell Kerr (Sales)

Tavistock

Tel: 020 7920 3150

Matt Ridsdale / Niall Walsh

 

 

Notes to Editors:

Founded in 2000, Benchmark represents a new model in sustainable business development. Over the last decade it has built a profitable group of companies on the economics of a sustainable food chain. The Company is growing in response to a rapidly increasing demand for sustainable food chains, and in particular for seafood, from both mature and emerging markets.

Benchmark is an ethical company with an explicit policy based on the "3E's" definition of a sustainable business - ethics, environment and economics - which guides its strategy and operations.

The group has five divisions: Animal Health which researches, manufactures and markets medicines and vaccines particularly for aquaculture, Sustainable Science which researches and informs sustainable development in the food industry, Technical Publishing which effects technology transfer through online publishing and education, Breeding and Genetics which comprises a world-leading Salmon and aquaculture breeding business, and Advanced Animal Nutrition which provides cutting edge nutritional products and services to the aquaculture industry. Benchmark operates internationally with offices in England, Scotland, Belgium, Ireland, Norway, Iceland, USA, Brazil, China, Moscow, India, Thailand and Chile. As at 1 May 2016, Benchmark employs 881 people.

For further information on Benchmark please visit www.benchmarkplc.com

 

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
TSTLFFLIESIEFIR
Date   Source Headline
23rd Jan 20187:08 amRNSFinal Results
19th Jan 20184:40 pmRNSSecond Price Monitoring Extn
19th Jan 20184:35 pmRNSPrice Monitoring Extension
5th Jan 20184:19 pmRNSHolding(s) in Company
4th Jan 20184:41 pmRNSSecond Price Monitoring Extn
4th Jan 20184:35 pmRNSPrice Monitoring Extension
12th Dec 20177:00 amRNSCommercial scale field trial of sea lice treatment
7th Dec 20177:00 amRNSBenchmark participates in gene editing research
5th Dec 20177:00 amRNSTrading Update and Notice of Results
8th Nov 20177:00 amRNSDevelopment of disease-resistant shrimp
6th Nov 201712:20 pmRNSReplacement: Directorate Change
6th Nov 20177:00 amRNSDirectorate Change
30th Oct 20177:00 amRNSLand-based Broodstock Facility Reaches Milestone
17th Oct 20177:00 amRNSNew Vaccine Facility Delivers First Production
10th Oct 20172:41 pmRNSHolding(s) in Company
21st Sep 20177:00 amRNSBlock Listing Six Monthly Return
8th Sep 20177:00 amRNSTrading Update
22nd Aug 20177:00 amRNSRenewal of Sales and Marketing Agreement
16th Aug 20177:00 amRNSLaunch of breakthrough purification system
28th Jul 20172:57 pmRNSDirector leave of absence
27th Jun 20177:02 amRNSHalf-year Report
19th Jun 20173:00 pmRNSNotice of Results
25th May 20177:00 amRNSTrading Update and Notice of Results
2nd May 20177:00 amRNSTotal Voting Rights
26th Apr 201710:54 amRNSDirector Dealings
3rd Apr 20174:32 pmRNSBlock Listing Six Monthly Return
9th Mar 20178:44 amRNSDirector Share Options and Issue of Shares
7th Mar 201710:39 amRNSResult of AGM
7th Mar 20178:00 amRNSContract Win
2nd Mar 20173:34 pmRNSHolding(s) in Company
1st Mar 20172:09 pmRNSHolding(s) in Company
23rd Feb 20177:00 amRNSHolding(s) in Company
22nd Feb 20174:35 pmRNSHolding(s) in Company
16th Feb 20177:45 amRNSDirector Dealings
24th Jan 20177:00 amRNSFinal Results
3rd Jan 20177:00 amRNSTotal Voting Rights
1st Dec 20167:00 amRNSDirector/PDMR Shareholding
29th Nov 20167:00 amRNSCapital Markets Day
25th Nov 20167:00 amRNSAppointment of Non-Executive Director
23rd Nov 20164:52 pmRNSHolding(s) in Company
26th Oct 20167:00 amRNSTrading Statement
12th Oct 20167:00 amRNSBlock Admission Application
10th Oct 201612:02 pmRNSBlock listing Interim Review
31st Aug 20167:00 amRNSBenchmark secures innovative new equine vaccine
12th Aug 201612:41 pmRNSHolding(s) in Company
11th Aug 20167:00 amRNSAcq of South American shrimp breeding programme
10th Aug 20163:37 pmRNSHolding(s) in Company
10th Aug 20161:40 pmRNSHolding(s) in Company
10th Aug 20161:33 pmRNSHolding(s) in Company
10th Aug 20161:29 pmRNSHolding(s) in Company

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.